\n<\/p>\n
April 24, 2026<\/p>\n
2 min read<\/p>\n<\/p><\/div>\n
\n \n \n Add topic to email alerts \n <\/span> \n <\/p>\n\n\n \n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nIndividuals who received duodenal mucosal resurfacing maintained more than 80% of their weight loss after tirzepatide withdrawal. <\/li>\nThe sham group regained about 40% more weight than duodenal mucosal group.<\/li>\n<\/ul>\nCHICAGO \u2014 Duodenal mucosal resurfacing helped prevent weight regain following tirzepatide discontinuation, according to research presented at Digestive Disease Week.<\/p>\nData from the randomized REMAIN-1 trial showed that individuals who did not undergo duodenal mucosal resurfacing (Revita, Fractyl Health) regained approximately 40% more weight than those who received the investigational outpatient procedure.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\nInterventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\nSullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\nThe trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
\n Receive an email when new articles are posted on \n <\/p>\n\n Please provide your email address to receive an email when new articles are posted on .<\/p><\/div>\n<\/p><\/div>\n “ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nIndividuals who received duodenal mucosal resurfacing maintained more than 80% of their weight loss after tirzepatide withdrawal. <\/li>\nThe sham group regained about 40% more weight than duodenal mucosal group.<\/li>\n<\/ul>\nCHICAGO \u2014 Duodenal mucosal resurfacing helped prevent weight regain following tirzepatide discontinuation, according to research presented at Digestive Disease Week.<\/p>\nData from the randomized REMAIN-1 trial showed that individuals who did not undergo duodenal mucosal resurfacing (Revita, Fractyl Health) regained approximately 40% more weight than those who received the investigational outpatient procedure.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\nInterventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\nSullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\nThe trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
“ \n data-action=”subscribe”> \n Subscribe \n <\/button>\n <\/div>\n<\/p><\/div>\n We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.<\/strong> <\/p>\nBack to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nIndividuals who received duodenal mucosal resurfacing maintained more than 80% of their weight loss after tirzepatide withdrawal. <\/li>\nThe sham group regained about 40% more weight than duodenal mucosal group.<\/li>\n<\/ul>\nCHICAGO \u2014 Duodenal mucosal resurfacing helped prevent weight regain following tirzepatide discontinuation, according to research presented at Digestive Disease Week.<\/p>\nData from the randomized REMAIN-1 trial showed that individuals who did not undergo duodenal mucosal resurfacing (Revita, Fractyl Health) regained approximately 40% more weight than those who received the investigational outpatient procedure.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\nInterventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\nSullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\nThe trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
Back to Healio<\/button><\/p>\n<\/div>\n<\/div><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/div>\nKey takeaways:<\/h2>\n\nIndividuals who received duodenal mucosal resurfacing maintained more than 80% of their weight loss after tirzepatide withdrawal. <\/li>\nThe sham group regained about 40% more weight than duodenal mucosal group.<\/li>\n<\/ul>\nCHICAGO \u2014 Duodenal mucosal resurfacing helped prevent weight regain following tirzepatide discontinuation, according to research presented at Digestive Disease Week.<\/p>\nData from the randomized REMAIN-1 trial showed that individuals who did not undergo duodenal mucosal resurfacing (Revita, Fractyl Health) regained approximately 40% more weight than those who received the investigational outpatient procedure.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\nInterventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\nSullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\nThe trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
CHICAGO \u2014 Duodenal mucosal resurfacing helped prevent weight regain following tirzepatide discontinuation, according to research presented at Digestive Disease Week.<\/p>\n
Data from the randomized REMAIN-1 trial showed that individuals who did not undergo duodenal mucosal resurfacing (Revita, Fractyl Health) regained approximately 40% more weight than those who received the investigational outpatient procedure.<\/p>\n \n \n \n \n <\/source><\/source><\/source><\/source><\/source><\/picture> \n \n <\/figcaption> \n <\/figure>\n\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\nInterventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\nSullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\nThe trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
\u201cThis procedure could fundamentally change how we think about GLP-1 therapy, providing an off-ramp for patients who either can\u2019t or don\u2019t want to be on these drugs long term with a minimally invasive procedure to lock in the metabolic benefits,\u201d Shelby Sullivan, MD,<\/b> director of the endoscopic bariatric and metabolic program at Dartmouth Health Weight Center and professor of medicine at Dartmouth Geisel School of Medicine, said in a media briefing prior to the meeting.<\/p>\n
GLP-1s are used by one in five adults with obesity, but nearly 70% of patients discontinue use within the first year, according to study background. Stopping the medications can lead to weight regain.<\/p>\n
Interventions are needed to prevent weight regain following GLP-1 cessation.<\/p>\n
\u201cGLP-1 medications have been a genuine breakthrough for people with obesity,\u201d Sullivan said. \u201cWhen these patients stop, the impact is twofold: The metabolic benefits are lost and … they experience a weight rebound, with most regaining their lost weight within 18 months on average.\u201d<\/p>\n
Sullivan and colleagues conducted the randomized, double-blind, sham-controlled REMAIN-1 trial to assess efficacy and safety of duodenal mucosal resurfacing following tirzepatide withdrawal.<\/p>\n
The trial included 45 adults (median age, 43 years; 80% women) with a BMI of 30 to 45 kg\/m2 <\/sup>who achieved at least 15% total body weight loss with tirzepatide before discontinuation. Eligible participants had no prior GLP-1 use and did not have diabetes.<\/p>\nResearchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\nAt 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\nAt 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\nAdditionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\nResearchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\nSix-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
Researchers randomly assigned individuals 2:1 at least 1 week after tirzepatide withdrawal to duodenal mucosal resurfacing (n = 29) or sham procedure (n = 16). Both cohorts received structured lifestyle counseling.<\/p>\n
At 3-month follow-up, individuals who underwent duodenal mucosal resurfacing lost an additional 2.1 kg on average, while patients in the sham group regained about 8.2 kg on average (treatment difference = 10.3 kg).<\/p>\n
At 6 months, patients who received the sham procedure regained approximately 40% more weight on average than those in the investigative group.<\/p>\n
Additionally, patients who underwent longer length tissue resurfacing maintained more than 80% of their weight loss. In comparison, patients in the sham group regained approximately twice the weight.<\/p>\n
Researchers noted no definite or probable treatment-emergent serious adverse events related to the procedure.<\/p>\n
\u201cWe know that weight regain after GLP-1 discontinuation is one of the most pressing unmet needs in obesity today,\u201d Sullivan said.<\/p>\n
\u201cThese early findings suggest that duodenal mucosal resurfacing may offer a real long-term solution, one that resets the gut\u2019s biology, rather than requiring lifelong pharmacotherapy,\u201d she added.<\/p>\n
Six-month primary endpoint data from the REMAIN-1 Pivotal Cohort is expected later this year.<\/p>\n
![\"Healio](\"https:\/\/www.healio.com\/~\/media\/h5\/feature\/news\/publogos\/hgld\/healio_gastro.svg?la=en&h=40&w=152&hash=2C654A538F2E250F5183D42A89FE0EC0\")
\n <\/div>\n<\/p><\/div>\n<\/p><\/div>\n